NEW PATENT ISSUED TO CANTEX PHARMACEUTICALS FOR ITS LEAD PRODUCT CANDIDATE IN THE TREATMENT OF THROMBOCYTOPENIA AND NEUTROPENIA
WESTON, Fla., Mar. 2, 2016 -- Cantex Pharmaceuticals, Inc. (“Cantex”), a clinical stage biopharmaceutical company developing proprietary compounds to enhance the efficacy and safety of the treatment of various cancers and related blood disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,271,999 to Cantex entitled, “Treatment of Myelosuppression”.
The patent, which will be in force until March 2033, provides proprietary protection for the use of the Company’s lead product candidate, known as CX 01, in the treatment of thrombocytopenia and neutropenia. The patent also covers use of related compounds in the treatment of thrombocytopenia and neutropenia. This new patent further fortifies the Company’s already robust patent portfolio, which includes 11 previously granted patents, including U.S. Patent 8,734,804, which provides proprietary protection until March 2033 for some uses of CX-01 in cancer treatment, as well as numerous pending patent applications.
Stephen G. Marcus, M.D., President and CEO of Cantex, commented, "This new patent for CX-01 is a significant addition to our intellectual property estate and provides proprietary protection for the use of CX-01 in thrombocytopenia, a condition of low platelets, and neutropenia, a condition in which there are inadequate infection-fighting white blood cells called neutrophils. We are exploring the efficacy and safety of CX-01 in a range of cancers and other illnesses in which thrombocytopenia and neutropenia may be a source of life-threatening complications."
About Cantex Pharmaceuticals, Inc.
Cantex is a clinical stage biopharmaceutical company focused on developing and commercializing proprietary compounds that enhance the efficacy and safety of the treatment of cancer and blood disorders. Cantex’s lead product candidate, CX-01, is a multi-targeted new chemical entity in development for the treatment of acute myeloid leukemia, myelodysplastic syndrome, acute graft versus host disease associated with allogeneic hematopoietic stem cell transplantation and non-small cell lung cancer. CX-01 is a long, unbranched, rationally engineered, negatively charged polysaccharide designed to block the activity of several chemokines that support the growth and spread of cancer and its resistance to treatment and that contribute to the delay of bone marrow recovery after chemotherapy. Cantex’s second product, CX-02, is in development for the treatment of glioblastoma. For more information, please visit www.cantex.com.